Johnson & Johnson stock heads into October 13 earnings report

Published on 10/06/2026 at 17:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock approaches its October 13 report after Q2 revenue reached USD 25.31 billion and EPS beat consensus by USD 0.06. Analysts see USD 276.09.

Comic-Illustration eines Wissenschaftlers mit Spritze und Impfstoffampulle — Pop-Art-Comic zeigt lächelnden Wissenschaftler mit Impfstoff und symbolisiert Innovationskraft von Johnson & Johnson, ISIN US4781601046, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at USD 253.86 on the NYSE on October 6, 2026 at 11:32 a.m. ET, up 0.37 percent from the prior close. The next major checkpoint is the company's Q3 2026 report, scheduled before the market opens on October 13, according to MarketBeat on October 6, 2026.

Q2 revenue beats consensus

Johnson & Johnson's Q2 2026 revenue was USD 25.31 billion, versus consensus of USD 25.06 billion, while quarterly revenue increased 6.6 percent year over year, MarketBeat reported. EPS reached USD 2.90, exceeding the USD 2.84 consensus by USD 0.06 in the quarter released on July 15, 2026.

The finance results for Q2 2026 show total revenue of USD 25.31 billion, consolidated net income of USD 5.534 billion and diluted GAAP EPS of USD 2.27. The difference between the reported EPS figures reflects the distinction between the adjusted quarterly figure cited by MarketBeat and the GAAP measure.

Consensus target sits above price

MarketBeat listed a Moderate Buy consensus on October 6, 2026, based on 25 analyst ratings, with an average target of USD 276.09. That target lies 8.8 percent above the USD 253.86 price, creating a clear valuation checkpoint ahead of the report.

MarketBeat also listed Bank of America at Neutral with a USD 278.00 target and JPMorgan at Neutral with a USD 285.00 target, both dated September 29, 2026. Zacks reported on October 5, 2026 that its consensus estimate called for Q3 revenue of USD 25.37 billion, up 5.75 percent from the prior-year quarter, while its full-year EPS estimate stood at USD 11.54.

Patent risk meets earnings date

The earnings release will test whether growth in Johnson & Johnson's newer medicines and medical devices can offset pressure from patent expirations. MarketBeat identified patent-expiration exposure as a key risk for 2027 revenue, while the October 13 report offers the next company-specific test of that replacement strategy.

Stock remains below yearly high

At USD 253.86 on the NYSE on October 6, 2026, Johnson & Johnson stock was 9.7 percent below its 52-week high of USD 281.07 and 38.8 percent above its 52-week low of USD 182.94. Market capitalization stood at USD 611.8 billion and volume reached 1,853,914 shares at 11:32 a.m. ET.